ESSA Pharma (NASDAQ:EPIX) Issues Quarterly Earnings Results

ESSA Pharma (NASDAQ:EPIX) (TSE:EPI) released its quarterly earnings data on Tuesday. The company reported ($0.14) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.19) by $0.05, Zacks reports.

ESSA Pharma Price Performance

Shares of ESSA Pharma stock opened at $1.63 on Tuesday. The stock has a market cap of $72.32 million, a PE ratio of -2.63 and a beta of 1.62. The firm has a fifty day moving average price of $3.18 and a 200 day moving average price of $4.67. ESSA Pharma has a 1 year low of $1.40 and a 1 year high of $11.67.

Insiders Place Their Bets

In related news, major shareholder Growth N. V. Biotech sold 7,879,583 shares of the business’s stock in a transaction on Friday, November 1st. The shares were sold at an average price of $1.53, for a total value of $12,055,761.99. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. 14.70% of the stock is owned by insiders.

Wall Street Analyst Weigh In

EPIX has been the subject of a number of recent research reports. Oppenheimer downgraded shares of ESSA Pharma from an “outperform” rating to a “market perform” rating in a report on Monday, November 4th. Piper Sandler cut shares of ESSA Pharma from an “overweight” rating to a “neutral” rating and decreased their target price for the company from $15.00 to $2.00 in a research report on Monday, November 4th. Finally, Jefferies Financial Group downgraded shares of ESSA Pharma from a “buy” rating to a “hold” rating in a research note on Monday, November 4th.

About ESSA Pharma

ESSA Pharma Inc, a clinical stage pharmaceutical company, focuses the development of small molecule drugs for the treatment of prostate cancer. The company’s lead candidate EPI-7386, an androgen receptor based resistance mechanisms that develop in patients with castration-resistant prostate cancer and metastatic castration-resistant prostate cancer.